At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 190 enrolled
Drug / intervention
VAY736 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)
In Brief
A Phase 2 clinical trial evaluating VAY736 and Placebo for Primary Sjogren Syndrome. Completed, enrolled 190 participants across 56 sites in 19 countries.
Detailed Summary
The purpose of this study was to determine the dose-response relationship of VAY736 for key efficacy and safety parameters
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sjogren Syndrome
CountriesArgentina, Austria, Belgium, Chile, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Portugal, Romania, Russia, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartJun 2017
Primary CompletionJun 2020
Study CompletionSep 2021
TodayJul 2026
First PostedNov 15, 2016
Enrollment StartJun 27, 2017
Primary CompletionJun 30, 2020
Study CompletionSep 23, 2021
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.6 years ago
Interventions
VAY736biological
VAY736
Placeboother
Placebo control